Skip to main content
. 2022 Oct 14;17(10):e0265478. doi: 10.1371/journal.pone.0265478

Table 2. Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Busia County Teaching & Referral Hospital (BCTRH), Busia.

15th April—21 May 2021 20 September– 22 October 2021
BCTRH, Busia Seroprevalence Adjusted seroprevalence Seroprevalence Adjusted seroprevalence
n / N % % 95% CI n / N % % 95% CI
All 78 / 270 28.9 30.6 24.7–37.1 195 / 297 65.7 70.7 64.1–77.4
Age
17–29 years 3 / 14 21.4 26.0 6.5–51.4 128 / 203 63.1 67.8 59.8–76.0
30–45 years 2 / 7 28.6 35.3 7.4–71.3 58 / 84 69.0 74.2 62.7–85.4
Trimester
First 18 / 51 35.3 38.2 25.1–52.6 50 / 78 64.1 68.7 56.6–80.1
Second 50 / 192 26.0 27.7 21.3–34.7 114 / 175 65.1 70.1 61.8–78.4
Third 7 / 22 31.8 35.3 17.3–55.8 26 / 39 66.7 71.2 54.3–86.4
Any symptoms in last month*
Yes 37 / 109 33.9 36.4 26.6–46.2 107 / 164 65.2 70.1 61.6–78.8
No 41 / 161 25.5 27.0 19.6–35.1 84 / 129 65.1 70.0 60.4–79.3
COVID-19 vaccination status
Vaccinated - - - - 4 / 6 66.7 67.0 29.8–96.1
Unvaccinated - - - - 188 / 288 65.3 70.5 63.8–77.3

1DOB was only available for 22 women in the first round of data collection.

* Women were asked about the full list of COVID-19 symptoms as per the MOH COVID-19 screening form i.e. fever/ chills, general weakness, cough, sore throat, runny nose, shortness of breath, diarrhoea, nausea/ vomiting, headache, irritability/ confusion, pain (muscular/ chest/ abdominal/ joint).

Vaccination status (at least one dose) was not available for the first two rounds of data collection, vaccination began in Kenya in March 2021 and at first targeted specific groups only, we assume that the vaccine coverage among women attended antenatal care between 27th Jan-11th March was 0%.

Variations in seroprevalence by any of the explanatory variables were not statistically significant in any time period when tested with chi2 test.